Board and executive changes at Xceleron
This article was originally published in Scrip
Xceleron, a company which accelerates drug development using ultra-sensitive bioanalytical analyses, has appointed Dr David Roblin to its board in a non-executive capacity, and Dr Stuart Best senior director of operations. Dr Roblin most recently served as senior vice-president of R&D, research head and site director at Pfizer Global R&D. Dr Best joins Xceleron from Merck where he was head of bioanalysis.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.